Summary The integrins are receptors that regulate interaction between epithelial cells and the extracellular matrix. Previous studies have shown that a reduction in the expression of the a2p1, a3p3l, a6p1, av31 and avP5 integrins in primary breast cancer is associated with positive nodal status. In order to assess the functional significance of altered integrin expression, primary breast cancer cells were derived from individual patients with known tumour characteristics using immunomagnetic separation. Purified human fibronectin, vitronectin, laminin and type IV collagen were used to represent the principal extracellular matrix proteins in an in vitro adhesion assay. Primary breast cancer cells from lymph node-positive patients were significantly less adhesive to each of the matrix proteins studied (P<0.001, Mann-Whitney Utest). Matrix adhesion of primary breast cancer cells from node-negative patients was inhibited by appropriate integrin monoclonal antibodies (P<0.001, paired Wilcoxon test). Adhesion to fibronectin, vitronectin and laminin, but not type IV collagen, was influenced by the inhibitor arginine-glycine-aspartate, suggesting that breast cancer cell recognition of collagen IV is mediated through alternative epitopes. Weak matrix adhesion correlated with loss of integrin expression in tissue sections from corresponding patients assessed using immunohistochemistry. This study demonstrates a link between altered integrin expression and function in primary breast cancers predisposed to metastasize.
Focal contact with the extracellular matrix is a fundamental mechanism by which cells initiate intracytoplasmic signalling in order to regulate attachment, migration, differentiation and growth (Burridge et al, 1988) . The anatomical basis for cell-matrix recognition is a group of transmembrane receptors called the cell adhesion molecules that include the integrins, cadherins, selectins and the immunoglobulin superfamily (Albelda and Buck, 1990) . The integrins are the principal receptors that facilitate cellular interaction to the extracellular matrix through binding to specific sites in fibronectin, vitronectin, laminin and collagen (Hynes, 1992) . The integrins consist of varying a and , subunits that associate to form heterodimers. Fourteen a and eight subunits have been identified that associate to form 20 known integrins, each categorized into subfamilies based upon the common ,B subunit (Hynes, 1987) . Each integrin heterodimer bears a receptor site towards the amino terminal in the extracellular domain. The carboxyl end is contained within the cell and provides a link to the cytoskeleton via the cytosolic proteins talin, vinculin and actin (Horwitz et al, 1986; Otey et al, 1993) . Intracellular signalling following ligation of integrin receptors is known to involve phosphorylation pathways (Kornberg et al, 1992) . Current attention has focused on a novel 125 kDa protein called focal adhesion kinase ppl25fak (Burridge et al, 1992) . Integrins signal into the cell, as conventional receptors, but, in addition, are also able to transmit information from within the cell to the matrix as well as to other cells via a mechanism termed inside-out signalling (Hynes, 1992) . The versatile nature of integrin function makes these receptors a critical point of study when cell-matrix interactions are considered.
Several unique peptide epitopes have been identified as recognition sequences for integrin receptors. The best characterized of these is the tripeptide arginine-glycine-aspartate, abbreviated to RGD (Humphries, 1990) . While RGD may be used as a general inhibitor of integrin function, specific receptor-ligand interaction may be investigated using monoclonal antibodies raised against the component subunits of each heterodimer (Yamada et al, 1990) . Altered cell-matrix interaction is an essential prerequisite step in the metastatic cascade (Hart and Saini, 1992) . Reduced integrin expression has been described in primary breast cancer cells compared with their benign counterparts (Zutter et al, 1990; Pignatelli et al, 1991; Koukoulis et al, 1991) , and altered function may be related to the presence of axillary nodal metastasis (Gui et al, 1995a ). We have previously described a method of isolating live human breast cancer cells from individual patients for use in short term in vitro studies of adhesion to laminin (Gui et al, 1995b) . The use of these patientderived cells is of obvious benefit compared with propagated cell lines in that it allows the study of breast cancers in women with known pathological characteristics and nodal status. The aim of this study was to evaluate cell-matrix adhesion in tumour progression. Fibronectin and vitronectin were used to assess cell adhesion to the interstitial matrix, while laminin and type IV collagen were used to represent the basement membrane. Our hypothesis was that human primary breast cancer cells that had lost integrin expression were less adhesive and therefore predisposed to metastasize. 
MATERIALS AND METHODS Patients

Immunomagnetic separation
The method of isolating breast cancer cells using immunomagnetic separation was modified from that of Motoyasu et al (1989) for bile duct epithelium and has been described in detail in our previous work (Gui et al, 1995b) . Briefly, fresh sterile breast cancer samples were transported in Dulbecco's modified Eagle medium (DMEM; Sigma) containing 4.5 g 1-1 glucose, 10% fetal bovine serum, 4 mmol 1-' L-glutamine, 2 mmol 1-1 sodium pyruvate, 10 ml 1-1 non-essential amino acids, 100 U ml-1 penicillin, 100 jig ml-streptomycin, 5 jg ml-l fungizone and 50 U ml-' polymyxin B (ICN Biomedicals, Thame, UK). Each breast cancer segment was disaggregated in collagenase (Gibco BRL, Paisley, UK) at 5 units mg-' tissue in DMEM containing 5% fetal bovine serum, 5 jg ml-' bovine insulin, 100 U ml-' penicillin, 100 jg ml-1 streptomycin, 5 jg mlF1 fungizone and 50 U ml-' polymyxin B on a vertical rotator at 37°C overnight. Cells were recovered by centrifugation at 900 r.p.m. and viability assessed using trypan blue exclusion (Sigma). Dynabeads M-450 (Dynal UK, Wirral, Merseyside, UK), precoated with rat anti-mouse IgG2a, were incubated with antibody to epithelial membrane antigen (EMA) (Taylor-Papadimitrou et al, 1981) (Dako, High Wycombe, Bucks, UK) to target breast cancer cells in the disaggregated suspension. The assay was performed at 4°C to prevent non-specific adhesion. The beads were detached by a combination of immunological methods (Rasmussen et al, 1992) using Detach-a-Bead (Dynal UK) and mechanical procedures (Gui et al, 1995b ).
Breast cancer cell clusters separated by the Magnetic Particle Container (Dynal UK) were dispersed into individual cells using 0.2% trypsin (ICN Biomedicals). The epithelial origin of the purified cell suspension was established by positive staining to EMA and the anti-human cytokeratin, CAM5.2, in conjunction with negative staining to the common leucocyte antigen CD45 and fibroblast markers (all from Dako UK). The malignant nature of the isolated cells was confirmed morphologically. Tissue samples were discarded, if adjacent cryostat sections contained recognizable 13.3(5-26) 12. 4(3-26) benign breast cells. The reliability of immunomagnetic separation as a method of producing breast cancer cell isolates and data on cell survival times have been established previously (Gui et al, 1995b ).
Histology and immunochemistry
Routine tumour and lymph node pathology was assessed on 3-jm paraffin-embedded sections stained with haematoxylin and eosin. All negative lymph nodes were, in addition, stained with CAM5.2 (Becton-Dickinson) to exclude occult metastasis. Immunohistochemistry was performed on 5-jim primary breast cancer cryostat sections using the avidin-biotin-peroxidase complex technique (Hsu et al, 1981) . Appropriate biotinylated antibodies and streptavidin peroxidase-conjugated antibodies (Dako UK) were used as secondary and tertiary layers respectively. All slides stained using immunohistochemistry were double read by two independent observers and scored as negative (-), weak (+), moderate (++) or strong (+++). Equivocal tumour cell staining was considered to be negative. Preservation of the integrin receptors after enzymatic disaggregation was confirmed by immunocytochemistry in cell smears snap frozen in liquid nitrogen.
In vitro adhesion assay
In preliminary studies, flat-bottomed 96-well plates were coated with graded concentrations (0.1-1000 jig ml-) of each of purified human fibronectin, vitronectin, laminin (Collaborative Biomedical Products, Oxford, UK) and type IV collagen (Sigma). These experiments demonstrated that maximal cell adhesion to each protein was achieved after a 4-h incubation period at matrix concentrations of 100 jg ml-1, and these parameters were selected as standard conditions for subsequent studies. Survival studies of primary breast cancer cell isolates based on trypan blue exclusion had shown viability in wells coated with these matrix proteins of up to 12 h after completion of immunomagnetic separation.
In the experiments described in this paper, all wells were rehydrated with 100 jig ml-' bovine serum albumin before use. The breast cancer cell suspension was diluted to contain 10 000 cells per ml in serum-free DMEM, and aliquots of 50 jl containing 500 cells were added to each well. Graded amounts of RGD, RGE (0-300 jig ml-1) or integrin monoclonal antibodies (0-150 jig ml-')
were used to inhibit cell-matrix adhesion. All experiments were conducted in triplicate at 37°C in a humidified carbon dioxide incubator. After incubation for 4 h, wells were washed and numbers of adherent cells estimated using spectrophotometric absorbance following uptake of 3-[4,5]dimethylthiazol-2-yl-2,5
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Variation in adhesion of primary breast cancer cells with nodal status is shown in Figure 1 . Adhesion of primary breast cancer cells from node-positive women to each of fibronectin, vitronectin, laminin and type IV collagen was significantly less than that of node-negative patients (P<O.OO1, Mann-Whitney U-test node-positive women were incubated for 8 h at 100 gg ml', and for 4 h at 1000 ,ug ml-' of each matrix protein with no demonstrable increase in cell adhesion. The inhibitory tripeptide RGD and specific integrin monoclonal antibodies were used to show that this difference in cell-matrix adhesion between lymph nodepositive and node-negative women was integrin mediated. Integrin expression was scored as strong (+++), moderate (++), weak (+), or negative staining (0) by two independent observers with consensus. Integrin function was expressed as the mean percentage of cell adhesion plated in triplicate wells. Strong and weak adhesion was considered to be greater or less than 50% cell-matrix adhesion respectively. Missing data arising from insufficient numbers of cells for an experimental set is shown wherever appropriate. Integrin subunits that were not applicable (NA) for a given matrix protein were not included. For non-parametric analysis, data for integrin expression were categorized into positive and negative by combining the strong, moderate and weak staining groups. P-values were derived using Fisher's exact test.
Variation in RGD inhibition
RGD, but adhesion to type IV collagen was unaffected by this tripeptide motif. Primary breast cancer cell adhesion to type IV collagen may, therefore, be mediated through alternative peptide recognition sequences. The control tripeptide RGE had no effect on breast cancer cell adhesion to the extracellular matrix. Primary breast cancer cells derived from lymph node-positive patients were unaffected by RGD, although any effect on cell-matrix adhesion may have been masked by weak adhesion even in the absence of inhibitory peptides.
Inhibition of primary breast cancer cell adhesion by integrin antibodies
Relevant antibodies to the integrins were tested against each of fibronectin, vitronectin, laminin and type IV collagen in primary breast cancer cells obtained from six consecutive integrin-positive tumours (Figure 4 ). Inhibition of cell-matrix adhesion by appropriate integrin monoclonal antibodies was achieved in a dose-dependent manner. Maximal inhibition of attachment was achieved at concentrations of 75 gg ml-' of each integrin monoclonal antibody for all the matrix proteins studied. PIF6, an inhibitory antibody against avP5, had no effect on primary breast cancer cell adhesion to fibronectin, even at a concentration of 150 gg ml-'. This suggests that avP5 expressed in human breast cancer cells is not a receptor for fibronectin. Each monoclonal antibody was used at concentrations of 75 pg ml-' to assess variation in the inhibition of cell-matrix adhesion with nodal status at 100 gg ml-' of each matrix protein ( Figure 5 A-D) . Primary breast cancer cells derived from lymph node-negative women demonstrated good adhesion to the extracellular matrix and were inhibited by appropriate integrin monoclonal antibodies. Cell adhesion to fibronectin was inhibited by antibodies to the a3 and PI subunits; vitronectin by 1 and P5; laminin by a2.
a3, a6 and f 1; and type IV collagen by a2, a3 and [ 1.
Primary breast cancer cells derived from lymph node-positive patients were poorly adherent to control wells that were incubated in the absence of inhibitory monoclonal antibodies. This intrinsic weak cell adhesion profile may conceal any potential effect of integrin monoclonal antibodies on cell-matrix interaction. 
DISCUSSION
Interaction between cancer cells and the extracellular matrix is known to influence tumour outcome (Ruoslahti, 1992) and may provide a mechanism by which certain tumour types are prone to metastasize. The cell adhesion molecules could be responsible for this phenomenon with variable expression and function of these receptors. Cell adhesion receptor function might be required for cancer cell interaction with the endothelium of lymphovascular channels and migration through the extracellular matrix at primary as well as secondary sites (Aznavoorian et al, 1990 ). On the other hand, down-regulation of cell adhesion molecule function might be expected in order for cancer cells to detach from the primary mass in the metastatic process. High integrin function is a recognized stop signal in the control of cell migration in embryogenesis (Duband et al, 1986 (Zutter et al, 1990; Pignatelli et al, 1991; Koukoulis et al, 1991; Gui et al, 1995a) , leading to the use of specific monoclonal antibodies to study function. Our results indicate that primary breast cancer cells from node-negative women were significantly more adherent to each of fibronectin, vitronectin, laminin and type IV collagen compared with primary breast cancer cells derived from node-positive patients (Figure 1 ). This was shown to be mediated, at least in part, by integrin interaction using the inhibitory tripeptide RGD (Figure 3) (Somogyi et al, 1994) . We were unable to demonstrate any RGD-mediated effect on cell adhesion to type IV collagen in this study.
The specific influence of each integrin receptor was then further assessed using monoclonal antibodies directed against individual subunits. Primary breast cancer cell-matrix adhesion of nodenegative women was significantly reduced compared with control wells using the paired Wilcoxon test (Figure 5 ). Inhibition of breast cancer cell adhesion by monoclonal antibodies in nodenegative women was consistent with previous knowledge of integrin receptor-ligand interactions (Hynes, 1992 (Languino et al, 1989) and collagen (Santoro et al, 1988 to be clarified. The mechanism by which integrin receptors are able to recognize multiple ligands is as yet uncertain. Integrin receptor heterodimers that bind to identical proteins are known to recognize specific epitopes that are spatially distinct on the matrix macromolecule (Humphries et al, 1987; Hall et al, 1990) . Integrin receptors undergo conformational change between an active and inactive state (Hynes, 1992) , and receptor activation may be influenced by a variety of factors. Modulation of integrin receptor function might be regulated by direct ligation of the receptor itself (outside-in signalling), a phenomenon associated with receptor clustering (Philips et al, 1988) . However, integrin expression is mainly thought to be regulated by inside-out signalling through a variety of tissue and soluble factors, including the cell adhesion molecule CD44 (Koopman et al, 1990 ), c-erbB-2 (D'Souza et al, 1993 , and the interleukins IL-12 (Rabinowich et al, 1993a ) and IL-6 (Rabinowich et al, 1993b) . Integrin expression is also dependent on the divalent cations calcium and manganese (Humphries, 1990) . The regulation of integrin receptor expression and function in tumour progression is currently being investigated in our laboratory.
The cellular effects modulated by integrin expression in tumour invasion may only be empirically related to cell-matrix adhesion. Loss of integrin expression may predispose to tumour progression by the loss of regulatory control over growth and differentiation. In in vitro studies, transfection of Chinese hamster ovary cells with the cDNA for the a5 PI fibronectin receptor inhibits the ability of these cells to grow and establish tumours in nude mice (Giancotti and Ruoslahti, 1990) . Cancer cells with decreased integrin expression may thus display greater invasive potential (Schreiner et al, 1991) .
The biology of tumour metastasis is still not well understood. We have shown that loss of integrin expression and function in primary breast cancer cells are related to reduced matrix adhesion in the presence of axillary nodal metastasis. Altered integrin-mediated adhesion of cancer cells to the extracellular matrix is a critical factor in the metastatic cascade. The integrins may, thus, be of clinical value as predictors of nodal status in patients with breast cancer at the time of symptomatic presentation. The prognostic significance of integrin expression in determining disease-free interval and overall survival in breast cancer progression remains to be defined.
